FDA Fast-Tracks Temab-A for Aggressive Lung Cancer Subtype

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Temab-A, a c-Met–directed antibody-drug conjugate (ADC), for the treatment of patients with EGFR wild-type nonsquamous non-small cell lung cancer (NSCLC) whose disease has progressed after platinum-based chemotherapy and anti–PD-(L)1 therapy. The designation was announced on [date] and aims to accelerate the development and regulatory review of Temab-A for this specific indication.

Breakthrough Therapy Designation is reserved for drugs that show preliminary clinical evidence of substantial improvement over existing therapies on one or more clinically significant endpoints. Temab-A targets c-Met, a receptor tyrosine kinase often overexpressed in NSCLC and associated with poor prognosis. This designation follows promising early-phase trial results demonstrating durable responses in heavily pretreated patients. The FDA's decision underscores the urgent need for new options in this patient population, which currently faces limited effective therapies after standard treatments fail.

This designation could significantly shorten Temab-A's path to market, providing a potential new treatment option for patients with c-Met–expressing nonsquamous NSCLC. It also highlights the growing role of ADCs in oncology and may spur further research into c-Met as a therapeutic target. The manufacturer is expected to work closely with the FDA to expedite the drug's development, with pivotal trials likely to be initiated or expanded in the coming months.